• Explore /
  • Poster
  • / A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Daniel Petrylak

Daniel Peter Petrylak

Yale University Medical Center, New Haven, CT

Daniel Peter Petrylak , David C. Smith , Leonard Joseph Appleman , Mark T. Fleming , Arif Hussain , Robert Dreicer , A. Oliver Sartor , Neal D. Shore , Nicholas J. Vogelzang , Hagop Youssoufian , William C. Olson , Nancy Stambler , Kathleen Huang , Robert Joseph Israel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01695044

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 83)

DOI

10.1200/jco.2014.32.4_suppl.83

Abstract #

83

Poster Bd #

E18

Abstract Disclosures

Similar Posters

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Johann S. De Bono